Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism

Kardiologia Polska

Volumn 70, Issue 5, 2012, Pages 439-445

  Gajos, Grzegorz ^a   Zalewski, Jarosław ^a   Nessler, Jadwiga ^a   Zmudka, Krzysztof ^a   Undas, Anetta ^a   Piwowarska, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angioplasty; Clopidogrel; CYP2C19 polymorphism; Fish oils

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; OMEGA 3 ACID ETHYL ESTER; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

EID: 84861670596     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2010; 31: 2501-2555.
2. Malek LA, Kisiel B, Spiewak M et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J, 2008; 72: 1165-1169. (Pubitemid 351957086)
3. Fefer P, Matetzky S. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature. Thromb Haemost, 2011; 106: 203-210.
4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003; 107: 2908-2913 (Pubitemid 36736631)
5. Tiroch KA, Sibbing D, Koch W et al. Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J, 2010; 160: 506-512.
6. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 2010; 304: 1821-1830.
7. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual anti-platelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol, 2010; 55: 1671-1678.
8. Larson MK, Shearer GC, Ashmore JH et al. Omega-3 fatty acids modulate collagen signaling in human platelets. Prostaglandins Leukot Essent Fatty Acids, 2011; 84: 93-98.
9. Serebruany VL, Miller M, Pokov AN et al. Early impact of prescription omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology, 2011; 118: 187-194.
10. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest, 1985; 76: 2446-2450. (Pubitemid 16155547)
11. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res, 2007; 121: 107-115. (Pubitemid 350025991)
12. Cuisset T, Quilici J, Cohen W et al. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome Am J Cardiol, 2011; 108: 760-765.
13. Gajos G. The fish oil story - back to Greenland? Cardiology, 2011; 118: 245-247.
14. Capdevila JH, Harris RC, Falck JR. Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci, 2002; 59: 780-789. (Pubitemid 34628239)
15. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res, 2009; 50: S52-S56.
16. Gryglewski RJ, Salmon JA, Ubatuba FB, Weatherly BC, Moncada S, Vane JR. Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins, 1979; 18: 453-478. (Pubitemid 10238959)
17. Fer M, Dréano Y, Lucas D et al. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys, 2008; 471: 116-125.
18. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun, 2005; 329: 1275-1281. (Pubitemid 40568707)
19. Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450- -dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep, 2010; 62: 536-547.
20. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost, 2010; 8: 1678-1684.
21. Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol, 2011; 31: 1696-1702.
22. Szułdrzyński K, Zalewski J, Machnik A, Zmudka K. Elevated levels of 8-iso-prostaglandin F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol Arch Med Wewn, 2010; 120: 19-24.
23. Undas A, Zalewski J, Krochin M et al. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol, 2010; 30: 276-282.